Drug Profile
PN 10943A
Alternative Names: PN-10943; PN-10943-A; PN-943; PTG-943Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Protagonist Therapeutics
- Class Anti-inflammatories; Peptides
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 27 Feb 2024 Discontinued - Phase-I for Inflammatory bowel diseases (In volunteers) in Australia (PO)
- 27 Feb 2024 Discontinued - Phase-II for Ulcerative colitis (Treatment-experienced) in USA, Hungary, Germany, Bulgaria, Canada, Poland, Austria, Georgia, Italy, South Korea, Russia, Serbia, Ukraine (PO)
- 16 Feb 2023 Protagonist Therapeutics completes the phase II IDEAL trial in Ulcerative colitis (Treatment-experienced) in USA, Austria, Georgia, Italy, South Korea, Russia, Serbia, Ukraine, Bulgaria, Germany, Canada, Poland, Hungary (PO) (NCT04504383) (EudraCT2019-004469-41)